主页 > 医药科学 >
【drug-news】国王药业试图收购Alpharma遭拒
The bid repesented a 49% premium to where Alpharma’s shares were trading when King made the offer, and a 37% premium to where the stock closed yesterday. But Alpharma went through the roof today when the bid was announced, and early this afternoon it was trading above King’s $33-per-share offer price.
Like many larger pharma companies, King has been struggling with patent problems. Last year, the company lost a patent lawsuit over its best-selling blood-pressure drug Altace. Earlier this month, the company said its second-quarter net income tumbled 34%, as Altace faced generic competition, the WSJ notes.
And, like many larger companies, King is looking to buy its way out of trouble. Alpharma recently launched a prescription patch for pain that brought in $37.7 million in its first quarter on the market, and hopes to launch another pain drug early next year.
Ken Trbovich, an analyst with RBC Capital Markets, told Bloomberg that other bidders — such as Endo, Cephalon or Johnson & Johnson, all of which already sell pain medicines — could swoop in to bid for Alpharma. “This puts them on the map with a ‘for sale’ sign in their yard, whether they wanted this or not,” he said. More pharma M&A action today, with King Pharmaceuticals announcing that Alpharma rejected a $1.4 billion cash buyout offer King made earlier this month. Alpharma’s decision to walk away from the offer — and the market’s reaction to today’s news — is yet another sign of the strong position held by small drug companies with products on the market.
今天越来越多的制药公司采取收购，国王制药在本月初宣布alpharma否决了一项14亿美元现金的收购。 alpharma的决定从提供-和市场反应的新闻-又是一个小型制药公司的产品在市场上站立脚的例子。
The bid repesented a 49% premium to where Alpharma’s shares were trading when King made the offer, and a 37% premium to where the stock closed yesterday. But Alpharma went through the roof today when the bid was announced, and early this afternoon it was trading above King’s $33-per-share offer price.
国王作出的要约，alpharmare股票代表了49%的奖金，以及昨天股票闭幕的37 ％的奖金。当宣布拍卖时，早在今下午前午贸易高达上述国王的33元的每股收购价，alpharma已经审查了 。
Like many larger pharma companies, King has been struggling with patent problems. Last year, the company lost a patent lawsuit over its best-selling blood-pressure drug Altace. Earlier this month, the company said its second-quarter net income tumbled 34%, as Altace faced generic competition, the WSJ notes.
像许多大制药公司，国王一直挣扎专利问题。去年，该公司失去了专利诉讼超过其最畅销的血压药物altace 。华尔街日报注意到，作为altace面对非专利的竞争，本月初，该公司表示其第二季度净所得下降34 ％ 。
And, like many larger companies, King is looking to buy its way out of trouble. Alpharma recently launched a prescription patch for pain that brought in $37.7 million in its first quarter on the market, and hopes to launch another pain drug early next year.
和许多人一样的大公司，国王正在寻求出路。 alpharma最近推出了疼痛的处方修补程序在上市第一季度赢得了三千七百七十○点零万美元，并希望明年年初开始另一疼痛药物。
Ken Trbovich, an analyst with RBC Capital Markets, told Bloomberg that other bidders — such as Endo, Cephalon or Johnson & Johnson, all of which already sell pain medicines — could swoop in to bid for Alpharma. “This puts them on the map with a ‘for sale’ sign in their yard, whether they wanted this or not,” he said.
RBC资本市场分析师Ken Trbovich告诉 Bloomberg ，其他投标人-如 Endo, Cephalon or Johnson & Johnson，所有这些都已经出售疼痛药物-可以一下子申办alpharma。 他说“这使得他们在区域内的地图上'出售'的迹象，不管他们是否希望这样”。 今天越来越多的制药公司采取收购，国王制药在本月初宣布alpharma否决了一项14亿美元现金的收购。 alpharma的决定从提供-和市场反应的新闻-又是一个小型制药公司的产品在市场上站立脚的例子。
国王作出的要约，alpharmare股票代表了49%的奖金，以及昨天股票闭幕的37 ％的奖金。当宣布拍卖时，早在今下午前午贸易高达上述国王的33元的每股收购价，alpharma已经审查了 。
像许多大制药公司，国王一直挣扎专利问题。去年，该公司失去了专利诉讼超过其最畅销的血压药物altace 。华尔街日报注意到，作为altace面对非专利的竞争，本月初，该公司表示其第二季度净所得下降34 ％ 。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-24 05:14
医学,生命科学网